Elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide (Genvoya)

Status:

Red

Decision Date:

April 2023

Comments

RED: Treatment of human immunodeficiency virus-1 infection without any known mutations associated with resistance to the integrase inhibitor class.

Red Drug Classifications

• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again